Feagan, B.G.

patient mucosal healing disease treatment bowel healing fliximab mucosal bowel preservation crohn preservation trial remission group therapy immunosuppression score expert panel consensus panel study expert surgery belgium management gastroenterology flammatory bowel disease result survey immunosuppression group abbott control corticosteroids azathioprine centocor number course hospitalization round university flammation factor proportion feagan certolizumab pegol tnf antagonists outcome schering delphi flammatory research antimetabolite methotrexate methylprednisolone response grant point antagonist endoscopic steering committee 1·00 management group centre topic meeting certolizumab fliximab treatment disease course consulting fees lecture fees table adalimumab fference bowel function netherland question complication pegol event corticosteroid